Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70218 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Xiangqing Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Chin…. Hauptthemen laut MEDLINE: Vancomycin, Hematologic Neoplasms, Anti-Bacterial Agents, Gram-Positive Bacterial Infections. Die Arbeit nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Vancomycin (VAN) remains the first‐line treatment for methicillin‐resistant, multidrug‐resistant gram‐positive bacterial infections, even among cancer patients. Patients with hematological malignancies (HMs) represent a unique population, whose physiological and pathological changes often differ from those of the general population. These variations may cause significant alterations in the in vivo pharmacokinetics (PK) of VAN, causing unpredictable changes in the safety, efficacy, and bacterial resistance. Customized dosing of VAN (CD van ) offers potential solutions to these challenges. However, there is currently a lack of guideline‐based, consensus‐driven references, and limited research on the implementation of CD van in HM patients, particularly in adults. This review concentrates on adult HM patients and reviews studies on VAN PK in them (including population PK and its models), focusing on current mainstream and novel CD van technologies, including therapeutic drug monitoring‐guided, model‐guided, closed‐loop control systems, and artificial intelligence‐guided CD van technologies. The challenges faced in the broader implementation of these technologies and the promising solutions exploited, such as blockchain technology‐driven clinical decision support systems, are also discussed. Understanding the multifaceted aspects of PK research and personalized dosing of VAN in HM patients will help facilitate the rational treatment of VAN, in‐depth PK research, and the development of CD van techniques in HM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
ORCID-Profile: Xiangqing Song
Förderung
- Hunan Provincial Natural Science Foundation of China
Zitieren
APA
Song, X., Zeng, M., Yang, T., & Han, M. (2026). Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70218
Vancouver
Song X, Zeng M, Yang T, Han M. Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70218
BibTeX
@article{Song2026,
author = {Song, Xiangqing and Zeng, Meizi and Yang, Tao and Han, Mi},
title = {Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70218}
}
EUVIMED